On November 7, 2019, the RAND Corporation convened a Technical Expert Panel (TEP) web meeting to gather input on analyses that could be conducted to further enhance the Medicare Advantage (MA) and Part D Contract Star Ratings program. In this meeting, RAND requested the TEP's input on: 1) consideration of new measures related to end-stage renal disease (ESRD) or chronic kidney disease (CKD) treatment; 2) generic prescribing measures; and 3) reporting at the parent organization level.
The TEP is composed of a diverse group of individuals with expertise across a wide range of disciplines including quality measurement, risk adjustment, statistical methods, and delivery of health care to Medicare beneficiaries enrolled in MA and Part D contracts. The TEP does not replace existing mechanisms to obtain broad stakeholder input regarding enhancements to the Star Ratings program.
The meeting summary includes a list of meeting attendees, summary of the meeting and discussions during the meeting, as well as analytic ideas that surfaced during discussions. The summary is organized by discussion topic, which maps to the content of the presentation. The presentation is a pdf version of the PowerPoint presentation given during the November 7th TEP meeting.
These conference proceedings should be of interest to affected stakeholders, researchers and policymakers focused on enhancing the MA and Part D contract Star Ratings system.
The research discussed at this conference was conducted by RAND Health Care.
This report is part of the RAND Corporation Conference proceeding series. RAND conference proceedings present a collection of papers delivered at a conference or a summary of the conference.
Our mission to help improve policy and decisionmaking through research and analysis is enabled through our core values of quality and objectivity and our unwavering commitment to the highest level of integrity and ethical behavior. To help ensure our research and analysis are rigorous, objective, and nonpartisan, we subject our research publications to a robust and exacting quality-assurance process; avoid both the appearance and reality of financial and other conflicts of interest through staff training, project screening, and a policy of mandatory disclosure; and pursue transparency in our research engagements through our commitment to the open publication of our research findings and recommendations, disclosure of the source of funding of published research, and policies to ensure intellectual independence. For more information, visit www.rand.org/about/research-integrity.
This document and trademark(s) contained herein are protected by law. This representation of RAND intellectual property is provided for noncommercial use only. Unauthorized posting of this publication online is prohibited; linking directly to this product page is encouraged. Permission is required from RAND to reproduce, or reuse in another form, any of its research documents for commercial purposes. For information on reprint and reuse permissions, please visit www.rand.org/pubs/permissions.
The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.